Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Geron Corporation’s $198 Million Upsized Public Offering
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
Nordic Capital’s Investment Into Equashield
Latham & Watkins LLP represented Nordic Capital in the transaction. Nordic Capital, a leading private equity investor, and Equashield have announced that Nordic Capital has joined Equashield’s...
Alpine Immune Sciences’ $100 Million Shares Offering
Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
Mirum Pharmaceuticals’ $80 Million Common Stock Offering
Cooley represented Mirum Pharmaceuticals, while Latham & Watkins represented the underwriters in the offering. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition,...
Boston Scientific’s Acquisition of Obsidio
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Arcutis Biotherapeutics’ $150 Million Shares Offering
Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
SK Capital’s Acquisition of Valtris Specialty Chemicals
Latham & Watkins represented SK Capital in the transaction. SK Capital Partners, a New York-based private investment firm focused exclusively on the specialty chemicals, materials, and...
Amgen’s $3.7 Billion Acquisition of ChemoCentryx
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
Patient Square Capital’s $1.25 Billion Acquisition of Hanger
Kirkland & Ellis, Greenberg Traurig, and Latham & Watkins advised Patient Square Capital, Foley & Lardner advised Hanger, Proskauer Rose advised Ares Capital Management LLC on...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...